drugset
drugset / Trial / NCT04043897

Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic Colitis

NCT04043897 ↗

Phase 2 Recruiting 10 enrolled Eugene F Yen, MD
NaSingle-groupOpen-labelTreatment

Summary

This is an open label study looking at rifaximin therapy for the treatment of microscopic (collagenous or lymphocytic) colitis.

Timeline

Start
2018-06-29
Primary completion
2021-12
Completion
2021-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Rifaximin Other / unclassified 550 mg Oral

Indications

microscopic colitis